Clinical Management and Control of Myopia in Children

Audrey Chia and Su Ann Tay

Key Points

• Our understanding of the pathogenesis and etiology of myopia continues to evolve, and with it, various interventions that prevent or slow the progression of myopia. These include the use of bifocal spectacles, peripheral defocus spectacles and contact lenses, orthokeratology contact lenses, atropine and environmental interventions.

• With various interventions available for myopia control, understanding the effectiveness, safety profile and cost of each intervention can aid the clinician in making collective decisions with patients and their families on the most appropriate intervention for each child.

• An atropine-based protocol for the treatment of myopia developed based on evidence from studies collected thus far is discussed. This includes assessment of risk factors for myopia progression, factors to consider when starting atropine, monitoring response to atropine treatment and factors to consider before cessation of treatment.

• It is important that there is continued assessment of the long-term effect and value of these treatments in preventing high myopia and its associated complications.
8.1 Introduction

The understanding of the pathogenesis of myopia and various interventions has evolved over time. The belief of an association between myopia and near work in the 1980s [1–5] led to interventions targeting accommodation such as bifocal glasses [6–8] and topical atropine [9–12]. The discovery of the importance of the peripheral retina [13–15], and how peripheral hyperopic defocus may aggravate eye growth and myopia [16–19] resulted in the exploration of peripheral defocus glasses and contact lenses as potential interventions in the 2000s. Induced peripheral myopic defocus is now thought to be how orthokeratology contact lenses slow myopia [16]. Research has moved on to novel contact lens designs, which also induce peripheral or dual defocus. More recently, it is hoped that with greater understanding of gene and molecular processes involved in eye growth, novel genetic and pharmacological treatments may be developed over time to control myopia.

8.2 Near Activity and Accommodation

8.2.1 Bifocal and Progressive Addition Spectacles

Progressive and bifocal glasses were introduced in the 1990s to try and slow myopia. However, studies with progressive addition lenses (PALs) showed a small and clinically insignificant or no effect on myopia progression [20–23]. One meta-analysis noted small reductions in myopia progression (0.25 D, 95% CI 0.13–0.38; nine trials) and axial length (−0.12 mm, 95% CI −0.18 to −0.05; six trials) [24]. This effect may be greater for children with a higher myopia (<−3.0 D), accommodative lag, or near esophoria [24–28].

In contrast, randomized controlled trials (RCTs) showed that executive bifocal lenses slowed myopia progression by 39% and up to 51% with base-in prisms incorporated [29]. It is possible that the larger near segment made it more likely for children to use the near add during near work, and may also induce more peripheral myopic defocus. However, because of the lack of collaborating evidence, meta-analysis across trials found data to be limited and inconsistent [20].

8.2.2 Atropine

Atropine is a non-specific muscarinic acetylcholine receptor antagonist and was initially thought to work by blocking accommodation. This theory has since been disproved in animal studies [30]. Its exact mechanism is still unknown but it is thought to work through muscarinic or non-muscarinic pathways either in the retina or in the sclera [31, 32]. Atropine has a strong dose-dependent inhibitory effect of myopia progression [30]. The initial high doses of atropine (i.e., 0.5% or 1.0%) slowed myopia progression by more than 70% over 1–2 years [33–36]. However, lower doses (0.1% or less) can also slow myopia by 30–60%, and may be associated with fewer side effects (pupil dilation, glare or blur) [36, 37]. Huang et al. in a review of the data, found that high-dose and low-dose atropine slowed spherical equivalent by 0.68 D
[0.52–0.84] and 0.53 D [0.21–0.85] respectively, and axial length by −0.21 mm
[−0.28 to −0.16] and −0.15 mm [−0.25 to −0.05] respectively over 1 year [38].

Washout data from the Atropine Treatment of Myopia (ATOM) studies, however,
showed that there was a myopic rebound if atropine was stopped suddenly,
especially at higher doses and in younger children [39, 40]. Up to 12% of children
may exhibit a poor response (i.e., progress >1.0 D over 1 year) even on high-dose
atropine. A poorer response was associated with younger children, a higher degree
of myopia at baseline and myopic parents [41]. Similarly, in the ATOM2 study,
9.3%, 6.4%, and 4.3% of children in the 0.01%, 0.1%, and 0.5% group, respectively,
progressed by 1.5 D or more in the first 2 years of treatment [42].

More recently, in the Low-Concentration Atropine for Myopia Progression
(LAMP) study involving children aged 4–12 years, those treated with 0.01%,
0.02%, and 0.05% atropine showed a reduction of SE progression of 27%, 43%, and
67%, and axial length growth of 12%, 29%, and 51%, respectively [37]. Overall, the
effect on spherical equivalent was larger than that of axial length.

8.3 Peripheral Defocus

From animal studies, it is known that eyeball growth (i.e., hyperopia or myopia)
could be induced by using positive and negative lenses, respectively [43, 44]. These
studies also showed that peripheral refraction could influence eye growth, indepen-
dent of central vision. Excessive near work could induce hyperopic defocus in the
peripheral retina and promote eye growth [25, 45–48]. The increased prolate growth
of the myopic eyeball and use of spherical glasses correcting for central vision may
aggravate this effect [46, 49–52]. Based on this theory, optical interventions that
induce a myopic defocus in the periphery should slow myopia.

8.3.1 Peripheral Myopic Defocus Glasses

In 2010, Sankaridurg et al. published their results of three novel spectacle lenses.
All lenses had a central clear aperture with varying amounts of plus defocus in
the periphery. Unfortunately, there was no significant effect on myopic progres-
sion with all three designs compared to single vision lenses (SVLs). In a sub-
group of younger children with parental myopia, however, the prototype where
the central aperture extended into the horizontal and inferior meridians with a
peripheral power of +1.9 D did result in less myopia progression [53]. However,
in a recent RCT conducted in Japanese children involving this design, no differ-
cence in myopia reduction was found [54].

8.3.2 Bifocal or Dual-Focus Contact Lenses

Bifocal contact lens designs often include a central distance focus, and peripheral
rings with near add, creating a peripheral myopic defocus. Studies exploring the
effect of these bifocal soft contact lenses indicate slowing of myopia progression by
30–38% and axial length by 31–51% over a period of 24 months [55–57]. Different studies suggest that efficacy may improve with increase in wear time, in children with faster rates of progression [58], near esophoria [59], and with designs possessing a higher hyperopic power in the mid-periphery (up to 6 D) [60]. With the myriad of lens designs possible, the challenge now is to develop the most effective design with the least compromise to visual quality, comfort, and safety [61].

8.3.3 Orthokeratology

Orthokeratology (Ortho-k) lenses optically correct myopia by flattening the central cornea, resulting in a relative peripheral myopic defocus [62, 63]. Individual studies and meta-analyses have shown a 40–60% reduction in the rate of myopia progression with ortho-k lenses compared with controls using SVL spectacles [64–69]. In a meta-analysis by Sun et al., the combined results showed a mean AL reduction of 0.27 mm (95% CI: 0.22, 0.32) after 2 years, corresponding to a 45% reduction in myopic progression [69]. Younger children (aged 7–8 years) with faster myopic progression (>1.0 D/year) might benefit more [66], and benefits were noted even in partially corrected children with high myopia [68]. However, studies show that the efficacy may decrease over time, especially after 4–5 years [70–72], and a potential “rebound” after discontinuation, especially in children under 14 years [73]. There is also a potential non-response rate of 7–12% [74, 75]. The risk of infective keratitis remains [76–81]; a recent systemic review suggested an infection rate similar to overnight wear of soft contact lenses, which is estimated at 13.9 per 10,000 [82, 83].

8.4 Time Spent Outdoors

While initial strategies were targeted at minimizing near work, it became apparent that increasing time spent outdoors could be more important [84, 85]. In the Sydney Myopia Study, exposure to more than 2 h of outdoor activity per day decreased the odds of myopia and countered the effects of near work [86]. Interventions involving increasing time outdoors appeared to reduce the onset of myopia and also its progression in myopic children [87, 88]. A meta-analysis has suggested a 2% reduced odds of myopia per additional hour of time spent outdoors per week [89]. Another meta-analysis showed that time outdoors protected children against incident myopia with a risk ratio (RR) of 0.536–0.574 in clinical trials and longitudinal cohort studies, and an odds ratio of 0.964 in cross-sectional studies, but had less effect in slowing progression in children who were already myopic [90].

8.4.1 Environmental Interventions

Based on new evidence, the advice has shifted from spending at least 2 h/day outdoors in addition to avoiding excessive near work. This has changed health and school messaging in many East Asian countries [88].
8.4.2 Higher Light Intensities and Dopamine

Potential reasons why time outdoors may be protective include higher light intensities [91, 92], differences in chromatic composition [93–95], the reduction in dioptric accommodative focus and psychometric influences encountered outdoors [96]. Higher light intensities increase retina dopamine production, which is believed to retard axial length elongation [97]. In animal studies, higher light levels greatly retarded form-deprivation myopia [91, 92, 98], a reaction which is abolished by dopamine antagonists [97]. The role of chromaticity (red and blue) and ultraviolet (UV) light is still uncertain [99–102], while that of higher vitamin D levels has been debunked [103, 104].

8.5 Inheritance and Genetics of Myopia

Epidemiology studies suggest that the risk of myopia is doubled if children had one myopic parent, and 3–5 times if they had two [105], with a possible additive effect with subsequent generations [106]. In addition, monozygous twins have a 75–90% chance of having a similar refraction compared to 30% in dizygous twins [107–109].

From pedigree analysis, multiple inheritance patterns (i.e., autosomal dominant, autosomal recessive, and X-linked) have been identified. Genome-wide sequencing analyses have identified more than 20 myopia and high myopia loci and over 130 potential genes (MYP1-3, 5–19) in different populations [107, 110]. These loci have been linked to neuronal signaling, retinoic acid synthesis, ion transport, channel activity, and membrane potential [110], which may influence ocular development, differentiation, and growth [111]. It is hoped that by understanding the genetics of myopia, it may be possible to predict who may develop high myopia or complications of myopia early, how people may respond to various interventions, and uncover novel interventions.

8.6 Application to Clinical Practice

In deciding on treatment regimes, questions on which children would benefit most from treatment in terms of age, baseline myopia, rate of progression, and family history remain. In addition, the appropriate duration of treatment and the best time to start, stop, and restart treatment need to be further studied. With the various interventions available for myopia control, decisions need to be made in conjunction with patients and their families on the most appropriate one, taking into consideration the effectiveness, safety profile, and cost of the each intervention (Table 8.1).

The following is an atropine-based protocol which has been developed, based on evidence collected thus far (Table 8.2 and Fig. 8.1). On presentation, the risk of the child developing myopia and its potential complications are assessed. Low-risk children may be older children (aged >11 years), those with little or no myopia progression in the last 1 year, and relatively low myopia. High-risk children may be those who have a strong family history of high myopia or myopic complications, are younger (<9 years), and with documented rapid progression of myopia over the last year. Parental and child
sentiments are also assessed (e.g., overall anxiety, willingness to administer eye drops every day, possibly till the child is in his/her mid-teens). Various options are discussed, ensuring that parents have realistic expectations of the outcome. The possibility of a poor response and need for a higher dose of atropine or alternative treatments are also carefully explained. Options would then include starting atropine or waiting another 6–12 months to monitor the natural progression of refraction.

In this protocol, children are first started on a lower dose of atropine with a plan to increase the dose as necessary. However, an alternative would be to start initially

| Table 8.1 Summary of interventions for myopia control efficacy, safety, and accessibility |
|-----------------------------------------------|----------------|----------------------------------------------------------------------------|
| Effectiveness                                      | Safety                  | Accessibility                                                   |
| Time outdoors                                    | Decrease onset of myopia by 30%; and progression of myopia by 18% [87, 88] | Safe. Requires sun protection of eyes and skin | Available to all. Limited by social factors (academic expectations), weather, and seasonal variations |
| Executive bifocal spectacles                     | Decrease myopia progression by 39%; 51% with base-in prisms incorporated [29] | Safe although may result in some visual distortion | Moderately expensive Readily available in most spectacle shops |
| PAL spectacles                                   | Decrease myopia progression 0–20% [24] |                                                                      |
| Peripheral myopic defocus spectacles              | No significant difference from SVL [53, 54] |                                                                      |
| Bifocal or dual focus soft contact lenses         | Decrease myopia progression 30–38% over 24 months [57] Better effect with near esophoria [59] | Possible risk of infective keratitis, contact lens intolerance No data on discontinuation and rebound effect | Moderately expensive although likely readily available in most spectacle shops |
| Orthokeratology contact lenses                   | 40–50% reduction in myopia progression over 1–2 years Effect may wane over time Rebound noted if stopped suddenly [69, 70] | Risk of infective keratitis similar to overnight soft CL wear: 13.9 per 10,000 [83] Ocular surface problems, corneal staining [82] | Can be expensive Require clinical expertise to ensure proper fit |
| Atropine                                         | Dose-related response for myopia control with 70–80% reduction with high dose (0.5–1%) [33–36] and 30–60% with low dose (0.01–0.05%) [36, 37] Rebound noted if stopped suddenly (esp. in younger children and at higher doses) [39, 40] | Glare and near blur with higher doses Allergy 1–4% Systemic effects rare Effect on spherical equivalent greater than axial length | Can be cost-effective if manufactured in bulk Lower doses not readily available in all communities |
Table 8.2 An atropine-based protocol for myopia treatment

A. Starting atropine
- Assess child’s risk of myopia
- High risk: family history of high myopia or myopic complications, younger age, documented rapid progression of myopia, poor life-style profile (outdoor–near work)
- Assess parents’ and children’s risk aversion to treatment, willingness to continue on treatment till at least teenage years
- Age 4–13 years of age with documented progression of myopia of at least >0.5 D in the last year

B1: Not keen on treatment: monitor over next 6–12 months
B2: Keen on treatment: commence atropine 0.01% daily for at least 2 years

C. Follow-up on treatment
- Review child every 6 months
- Monitor for compliance and side effects: near blur, glare, and allergy
- Cycloplegic refraction and axial length measurements at least once per year

D1: Good or acceptable response to treatment (<0.5 D/year)
- Age <12 years old: consider continuing dose or slowly taper if no myopia progression noted in the past year
- Age >12 years old: consider taper of medication if no/little progression noted in the past year

D2: Poor response to treatment (>0.5 D/year)
- Particularly in younger children (<9 years), with strong family history, with baseline high myopia and rapid progression prior to starting atropine
- Consider an increased dose (e.g., atropine 0.01% 2× per day, 0.1% daily or 1.0% 2–3× per week)
- Consider tinted glasses with near add if required
- Once stabilization of myopia is achieved, continue at that dose, and taper frequency of drops as child reaches teenage years

D3: Poor response despite maximum atropine dose
- Consider stopping and changing or adding different treatment options

E. Long-term follow-up
- Continue to monitor child for at least 1 year after stopping treatment

on a higher dose, with an aim to taper medication over time. Once medication is started, progression (refraction and/or axial length) is monitored every 6 months, with an initial aim to continue children on medication (i.e., atropine 0.01% daily) for at least 2 years. Children may respond to treatment in three ways: well (with little or no progression); adequately (with acceptable amount of progression, e.g., <0.5 D/year); or poorly (>0.5 D/year).

If a good response is obtained, the next question is how long treatment should continue for and when treatment should be stopped. From the ATOM 2 study, we know that stopping atropine 0.01% between 8 and 10 years resulted in a 60% risk of a rebound effect, compared to 30% at age 10–12 years and 8% after the age of 12 years. In addition, children who did not demonstrate rebound tended to show little or no myopic progression within the last year [67]. This suggests that in children younger than 12 years who showed no progression in the past year, atropine 0.01% may be slowly tapered (e.g., by reducing drop frequency by 1–2 days/week each year). However, if children are older than 12 years, then the frequency of eye drops could be tapered more quickly (e.g., by 1–2 days/week every 6 months). Using this regime, most children will be off medication by about 14–15 years of age.
In children who progress on low-dose atropine, the frequency of application or dose could be increased (e.g., using atropine 0.01% twice a day; or using a higher concentration, e.g., 0.1% or 1%). Note that while using higher concentrations, a daily dose may not be necessary and children may require tinted glasses with near add to cope with any glare or near blur. Once an adequate control of myopia is achieved, medication can be continued till the child reaches teenage years and then tapered as required. There are some children (10%), however, who may progress rapidly even on higher doses of atropine [68]. If this occurs, then the possibility of stopping treatment or trying other treatment modalities should be discussed. Even after stopping treatment, it may be necessary to monitor children for a further 6–12 months to ensure that there is no further rebound.

Since our knowledge of how children respond to atropine and other interventions continues to increase over time, any protocol developed needs to be evaluated regularly, taking full advantage of our knowledge and accessibility to different treatment options.

### 8.7 Conclusion

Our management of myopia continues to evolve over time with a better understanding of the pathogenesis of myopia and its interventions. The challenge is to identify which individuals to treat, when to start treatment and which
interventions one should use. There are differences in efficacy, safety, and cost which need to be balanced. More work is required to determine how to combine or time treatments to optimize outcome, and when treatments can be safely stopped. It is also important that there is continued assessment of the long-term effect and value of these treatments in preventing high myopia and its associated complications.

References

1. Parssinen O, Lyyra AL. Myopia and myopic progression among schoolchildren: a three-year follow-up study. Invest Ophthalmol Vis Sci. 1993;34:2794–802.
2. Goss DA. Nearwork and myopia. Lancet. 2000;356:1456–7.
3. Hepsen IF, Evereklioglu C, Bayramlar H. The effect of reading and near-work on the development of myopia in emmetropic boys: a prospective, controlled, three-year follow-up study. Vis Res. 2001;41:2511–20.
4. Saw SM, Chua WH, Hong CY, et al. Nearwork in early-onset myopia. Invest Ophthalmol Vis Sci. 2002;43:332–9.
5. Li SM, Li SY, Kang MT, et al. Near work related parameters and myopia in Chinese children: The Anyang Childhood Eye Study. PLoS One. 2015;10:e0134514.
6. Goss DA. Effect of bifocal lenses on the rate of childhood myopia progression. Am J Optom Physiol Optic. 1986;63:135–41.
7. Parssinen O, Hemminki E, Klemetti A. Effect of spectacle use and accommodation on myopic progression: final results of a three-year randomised clinical trial among schoolchildren. Br J Ophthalmol. 1989;73:547–51.
8. Grosvenor T, Perrigin DM, Perrigin J, Maslovitz B. Houston Myopia Control Study: a randomized clinical trial. Part II. Final report by the patient care team. Am J Optom Physiol Optic. 1987;64:482–98.
9. Bedrossian RH. The effect of atropine on myopia. Ann Ophthalmol. 1971;3:891–7.
10. Gimbel HV. The control of myopia with atropine. Can J Ophthalmol. 1973;8:527–32.
11. Bedrossian RH. The effect of atropine on myopia. Ophthalmology. 1979;86:713–9.
12. Brodstein RS, Brodstein DE, Olson RJ, et al. The treatment of myopia with atropine and bifocals. A long-term prospective study. Ophthalmology. 1984;91:1373–9.
13. Wallman J, Gottlieb MD, Rajaram V, et al. Local retinal regions control local eye growth and myopia. Science. 1987;237:73–8.
14. Dietler S, Schaeffel F. Local changes in eye growth induced by imposed local refractive error despite active accommodation. Vis Res. 1997;37:659–68.
15. Miles FA, Wallman J. Local ocular compensation for imposed local refractive error. Vis Res. 1990;30:339–49.
16. Wallman J, Winawer J. Homeostasis of eye growth and the question of myopia. Neuron. 2004;43:447–68.
17. Smith EL, Hung LF, Ramamirtham R, et al. Optically imposed hyperopic defocus in the periphery can produce central axial myopia in infant monkeys. Invest Ophthalmol Vis Sci. 2007;48(13):1533.
18. Smith EL, Hung LF, Huang J. Relative peripheral hyperopic defocus alters central refractive development in infant monkeys. Vis Res. 2009;49:2386–92.
19. Smith EL, Hung LF, Huang J, et al. Effects of optical defocus on refractive development in monkeys: evidence for local, regionally selective mechanisms. Invest Ophthalmol Vis Sci. 2010;51:3864–73.
20. Walline JJ, Lindsley K, Vedula SS, et al. Interventions to slow progression of myopia in children. Cochrane Database Syst Rev. 2011;12:CD004916.
21. Gwiazda JE, Hyman L, Everett D, The COMET Group, et al. Five–year results from the correction of myopia evaluation trial (COMET). Invest Ophthalmol Vis Sci. 2006;47(13):1166.
22. Hasebe S, Ohtsuki H, Nonaka T, et al. Effect of progressive addition lenses on myopia progression in Japanese children: a prospective, randomized, double-masked, crossover trial. Invest Ophthalmol Vis Sci. 2008;49(7):2781–9.
23. Hasebe S, Jun J, Vamas SR, et al. Myopia control with positively aspherised progressive addition lenses: a 2 year, multicentre, randomized, controlled trial. Invest Ophthalmol Vi Sci. 2014;55(11):7177–88.
24. Li SM, Ji YZ, Wu SS, et al. Multifocal versus single vision lenses intervention to slow progression of myopia in school-age children: a meta-analysis. Surv Ophthalmol. 2011;56:451–60.
25. Gwiazda JE, Hyman L, Norton TT, COMET Group, et al. Accommodation and related risk factors associated with myopia progression and their interaction in COMET children. Invest Ophthalmol Vis Sci. 2004;45(7):2143–51.
26. Correction of Myopia Evaluation Trial 2 Study Group for the Pediatric Eye Disease Investigator Group. Progressive-addition lenses versus single-vision lenses for slowing progression of myopia in children with high accommodative lag and near esophoria. Invest Ophthalmol Vis Sci. 2011;52:2749–57.
27. Berntsen DA, Sinnott LT, Mutti DO, Zadnik K. A randomized trial using progressive addition lenses to evaluate theories of myopia progression in children with a high lag of accommodation. Invest Ophthalmol Vis Sci. 2012;53:640–9.
28. Yang Z, Lan W, Ge J, Liu W, Chen X, Chen L, Yu M. The effectiveness of progressive addition lenses on the progression of myopia in Chinese children. Ophthalmic Physiol Opt. 2009;29:41–8.
29. Cheng D, Woo GC, Drobe B, Schmid KL. Effect of bifocal and prismatic bifocal spectacles on myopia progression in children: three-year results of a randomized clinical trial. Ophthalmology. 2014;132:258–64.
30. McBrien NA, Moghaddam HO, Reeder AP. Atropine reduces experimental myopia and eye enlargement via a nonaccommodative mechanism. Invest Ophthalmol Vis Sci. 1993;34:205–15.
31. McBrien NA, Stell WK, Carr B. How does atropine exert its anti-myopia effects? Ophthalmic Physiol Opt. 2013;33(3):373–8.
32. Lind GJ, Chew SJ, Marzani D, Wallman J. Muscarinic acetylcholine receptor antagonists inhibit chick scleral chondrocytes. Invest Ophthalmol Vis Sci. 1998;39:2217–31.
33. Yen MY, Liu JH, Kao SC, Shiao CH. Comparison of the effect of atropine and cyclopentolate on myopia. Ann Ophthalmol. 1989;21:180–2.
34. Shih YF, Chen CH, Chou AC, et al. Effects of different concentrations of atropine on controlling myopia in myopic children. J Ocul Pharmacol Ther. 1999;15:85–90.
35. Chua WH, Balakrishnan V, Chan YH, et al. Atropine for the treatment of childhood myopia. Ophthalmology. 2006;113(12):2285–91.
36. Chia A, Chua WH, Cheung YB, et al. Atropine for the treatment of childhood myopia: safety and efficacy of 0.5%, 0.1%, and 0.01% doses (Atropine for the Treatment of Myopia 2). Ophthalmology. 2012;119(2):347–54.
37. Yam JC, Jiang Y, Tang SM, et al. Low-concentration atropine for myopia progression (LAMP) study: a randomized, double-blinded, placebo-controlled trial of 0.05%, 0.025%, and 0.01% atropine eye drops in myopia control. Ophthalmology. 2019;126(1):113–24.
38. Huang J, Wen D, Wang Q, et al. Efficacy comparison of 16 interventions for myopia control in children: a network meta-analysis. Ophthalmology. 2016;123(4):697–708.
39. Tong L, Huang XL, Koh AL, et al. Atropine for the treatment of childhood myopia: effect on myopia progression after cessation of atropine. Ophthalmology. 2009;116:572–9.
40. Chia A, Chua WH, Wen L, et al. Atropine for the treatment of childhood myopia: changes after stopping atropine 0.01%, 0.1% and 0.5%. Am J Ophthalmol. 2014;157(2):451–457.e1.
41. Loh KL, Lu Q, Tan D, Chia A. Risk factors for progressive myopia in the atropine therapy for myopia study. Am J Ophthalmol. 2015;159:945–9.
42. Chia A, Lu QS, Tan D. Five-year clinical trial on atropine for the treatment of myopia 2: myopia control with atropine 0.01% eyedrops. Ophthalmology. 2016;123(2):391–9.
43. Troilo D, Wallman J. The regulation of eye growth and refractive state: an experimental study of emmetropization. Vis Res. 1991;31:1237–50.
44. Schaeffel F, Troilo D, Wallman J, Howland HC. Developing eyes that lack accommodation grow to compensate for imposed defocus. Vis Neurosci. 1990;4:177–83.
45. Seidemann A, Schaeffel F. An evaluation of the lag of accommodation using photorefraction. Vis Res. 2003;43:419–30.
46. Gwiazda J, Bauer J, Thorn F, et al. A dynamic relationship between myopia and blur-driven accommodation in school-aged children. Vis Res. 1995;35:1299–304.
47. Gwiazda J, Thorn F, Bauer J, et al. Myopic children show insufficient accommodative response to blur. Invest Ophthalmol Vis Sci. 1993;34:690–4.
48. Charman WN. Near vision, lags of accommodation and myopia. Ophthalmic Physiol Opt. 1999;19:126–33.
49. Mutti DO, Sinnott LT, Mitchell GL, CLEERE Study Group, et al. Relative peripheral refractive error and the risk of onset and progression of myopia in children. Invest Ophthalmol Vis Sci. 2011;52(1):199–205.
50. Atchison DA, Jones CE, Schmid KL, et al. Eye shape in emmetropia and myopia. Invest Ophthalmol Vis Sci. 2004;45(10):3380–6.
51. Schmid GF. Association between retinal steepness and central myopic shift in children. Optom Vis Sci. 2011;88(6):684–90.
52. Sng CCA, Lin XY, Gus G, et al. Change in peripheral refraction over time in Singapore Chinese children. Invest Ophthalmol Vis Sci. 2011;52(11):7880–7.
53. Sankaridurg P, Donovan L, Varnas S, et al. Spectacle lenses designed to reduce progression of myopia: 12-month results. Optom Vis Sci. 2010;87(9):631–41.
54. Kanda H, Oshika T, Hiraoka T, et al. Effect of spectacle lenses designed to reduce relative peripheral hyperopia on myopia progression in Japanese children: a 2-year multicenter randomised controlled trial. Jpn J Ophthalmol. 2018;62:537–43.
55. Benavente-Pérez A, Nour A, Troilo D. Axial eye growth and refractive error development can be modified by exposing the peripheral retina to relative myopic or hyperopic defocus. Invest Ophthalmol Vis Sci. 2014;55(10):6765–73.
56. Walline JJ. Myopia control: a review. Eye Contact Lens. 2016;42(1):3–8.
57. Li SM, Kang MT, Wu SS, et al. Studies using concentric ring bifocal and peripheral add multifocal contact lenses to slow myopia progression in school-aged children: a meta-analysis. Ophthalmic Physiol Opt. 2017;37(1):51–9.
58. Lam CSY, Tang WC, Tse DY-Y, Tang YY, To CH. Defocus incorporated soft contact (DISC) lens slows myopia progression in Hong Kong Chinese schoolchildren: a 2-year randomised clinical trial. Br J Ophthalmol. 2014;98:40–5.
59. Aller TA, Liu M, Wildsoet CF. Myopia control with bifocal contact lenses: a randomized clinical trial. Optom Vis Sci. 2016;93(4):344–52.
60. Paune J, Morales H, Armengol J, et al. Myopia control with a novel peripheral gradient soft lens and orthokeratology: a 2-year clinical trial. Biomed Res Int. 2015;2015:507572.
61. Anstice NS, Phillips JR. Effect of dual-focus soft contact lens wear on axial myopia progression in children. Ophthalmology. 2011;118:1152–61.
62. Charman WN, Mountford J, Atchison DA, et al. Peripheral refraction in orthokeratology patients. Optom Vis Sci. 2006;83:641–8.
63. Queirós A, González-Méijome JM, Jorge J, et al. Peripheral refraction in myopic patients after orthokeratology. Optom Vis Sci. 2010;87(5):323–9.
64. Wen D, Huang J, Chen H, et al. Efficacy and acceptability of orthokeratology for slowing myopic progression in children: a systematic review and meta-analysis. J Ophthalmol. 2015;2015:360806.
65. Si JK, Tang K, Bi HS, et al. Orthokeratology for myopia control: a meta-analysis. Optom Vis Sci. 2015;92:252–7.
66. Cho P, Cheung SW, Edwards M, et al. The longitudinal orthokeratology research in children (LORIC) in Hong Kong: a pilot study on refractive changes and myopic control. Curr Eye Res. 2005;30:71–80.
67. Santodomingo-Rubido J, Villa-Collar C, Gilmartin B, et al. Myopia control with orthokeratology contact lenses in Spain: refractive and biometric changes. Invest Ophthalmol Vis Sci. 2012;53:5060–5.
68. Charm J, Cho P. High myopia partial reduction ortho-k: a 2-year randomized study. Optom Vis Sci. 2013;90:530–9.
69. Sun Y, Xu F, Zhang T, Liu M, Wang D, Chen Y, Liu Q. Orthokeratology to control myopia progression: a meta-analysis. PLoS One. 2015;10(4):e0124535.
70. Hiraoa T, Kakita T, Okamoto F, et al. Long-term effect of overnight orthokeratology on axial length elongation in childhood myopia: a 5-year follow-up study. Invest Ophthalmol Vis Sci. 2012;53:3913–9.
71. Lee YC, Wang JH, Chiu CJ. Effect of Orthokeratology on myopia progression: twelve-year results of a retrospective cohort study. BMC Ophthalmol. 2017;17(1):243.
72. Santodomingo-Rubido J, Villa-Collar C, Gilmartin B, Gutiérrez-Ortega R, Sugimoto K. Long-term efficacy of orthokeratology contact lens wear in controlling the progression of childhood myopia. Curr Eye Res. 2017;42(5):713–20.
73. Cho P, Cheung SW. Discontinuation of orthokeratology on eyeball elongation (DOEE). Cont Lens Anterior Eye. 2017;40:82–7.
74. Cho P, Cheung SW. Retardation of myopia in orthokeratology (ROMIO) study: a 2-year randomized clinical trial. Invest Ophthalmol Vis Sci. 2012;53:7077–85.
75. Chen C, Cheung SW, Cho P. Myopia control using toric orthokeratology (TO-SEE Study). Invest Ophthalmol Vis Sci. 2013;54(10):6510–7.
76. Sun X, Zhao H, Deng S, et al. Infectious keratitis related to orthokeratology. Ophthalmic Physiol Opt. 2006;26:133–6.
77. Yepes N, Lee SB, Hill V, et al. Infectious keratitis after overnight orthokeratology in Canada. Cornea. 2005;24:857–60.
78. Tseng CH, Fong CF, Chen WL, et al. Overnight orthokeratology-associated microbial keratitis. Cornea. 2005;24:778–82.
79. Young AL, Leung AT, Cheng LL, et al. Orthokeratology lens-related corneal ulcers in children: a case series. Ophthalmology. 2004;111:590–5.
80. Xuguang S, Lin C, Yan Z, et al. Acanthamoeba keratitis as a complication of orthokeratology. Am J Ophthalmol. 2003;136:1159–61.
81. Chan TC, Li EY, Wong VW, Jhanji V. Orthokeratology-associated infectious keratitis in a tertiary care eye hospital in Hong Kong. Am J Ophthalmol. 2014;158:1130–5.
82. Liu YM, Xie P. The safety of orthokeratology—a systematic review. Eye Contact Lens. 2016;42:35–42.
83. Meter V, Woodford S, et al. Safety of overnight orthokeratology for myopia. Ophthalmology. 2008;115(12):2301–13.
84. Guggenheim JA, Northstone K, McMahon G, et al. Time outdoors and physical activity as predictors of incident myopia in childhood: a prospective cohort study. Invest Ophthalmol Vis Sci. 2012;53(6):2856–65.
85. Rose KA, Morgan IG, Smith W, Burlutsky G, Mitchell P, Saw SM. Myopia, lifestyle, and schooling in students of Chinese ethnicity in Singapore and Sydney. Arch Ophthalmol. 2008;126(4):527–30.
86. Rose KA, Morgan IG, Ip J, Kifley A, Huynh S, Smith W, Mitchell P. Outdoor activity reduces the prevalence of myopia in children. Ophthalmology. 2008;115(8):1279–85.
87. He M, Xiang F, Zeng Y, et al. Effect of time spent outdoors at school on the development of myopia among children in China: a randomized clinical trial. JAMA. 2015;314(11):1142–8.
88. Wu PC, Chen CT, Lin KK, et al. Myopia prevention and outdoor light intensity in a school-based cluster randomized trial. Ophthalmology. 2018;125(8):1239–50.
89. Sherwin JC, Reacher MH, Keogh RH, et al. The association between time spent outdoors and myopia in children and adolescents: a systematic review and meta-analysis. Ophthalmology. 2012;119:2141–51.
90. Xiong S, Sankaridurg P, Naduvilath T, Zang J, Zou H, Zhu J, Lv M, He X, Xu X. Time spent in outdoor activities in relation to myopia prevention and control: a meta-analysis and systematic review. Acta Ophthalmol. 2017;95(6):551–66.
91. Ashby R, Ohlendorf A, Schaeffel F. The effect of ambient illuminance on the development of deprivation myopia in chicks. Invest Ophthalmol Vis Sci. 2009;50:5348–54.
92. Karouta C, Ashby RS. Correlation between light levels and the development of deprivation myopia. Invest Ophthalmol Vis Sci. 2015;56:299–309.
93. Rohrer B, Schaeffel F, Zrenner E. Longitudinal chromatic aberration and emmetropization: results from the chicken eye. J Physiol. 1992;449:363–76.
94. Seidemann A, Schaeffel F. Effects of longitudinal chromatic aberration on accommodation and emmetropization. Vis Res. 2002;42:2409–17.
95. Rucker FJ, Wallman J. Chick eyes compensate for chromatic simulations of hyperopic and myopic defocus: evidence that the eye uses longitudinal chromatic aberration to guide eye growth. Vis Res. 2009;49:1775–83.
96. Flitcroft DI. The complex interactions of retinal, optical and environmental factors in myopia aetiology. Prog Retin Eye Res. 2012;31:622–60.
97. Feldkaemper M, Schaeffel F. An updated view on the role of dopamine in myopia. Exp Eye Res. 2013;114:106–19.
98. Smith EL 3rd, Hung LF, Huang J. Protective effects of high ambient lighting on the development of form-deprivation myopia in rhesus monkeys. Invest Ophthalmol Vis Sci. 2012;53:421–8.
99. Prepas SB. Light, literacy and the absence of ultraviolet radiation in the development of myopia. Med Hypotheses. 2008;70:635–7.
100. Foulds WS, Barathi VA, Luu CD. Progressive myopia or hyperopia can be induced in chicks and reversed by manipulation of the chromaticity of ambient light. Invest Ophthalmol Vis Sci. 2013;54(13):8004–12.
101. Smith EL, Hung LF, Arumugam B, et al. Effects of long-wavelength lighting on refractive development in infant rhesus monkeys. Invest Ophthalmol Vis Sci. 2015;56(11):6490–500.
102. Hung LF, Arumugam B, She Z, et al. Narrow-band, long-wavelength lighting promotes hyperopia and retards vision-induced myopia in infant rhesus monkeys. Exp Eye Res. 2018;4(176):147–60.
103. Guggenheim JA, Williams C, Northstone K, et al. Does vitamin D mediate the protective effects of time outdoors on myopia? Findings from a prospective birth cohort. Invest Ophthalmol Vis Sci. 2014;55:8550–8.
104. Cuellar-Partida G, Williams KM, Yazar S, et al. Genetically low vitamin D concentrations and myopic refractive error: a Mendelian randomization study. Int J Epidemiol. 2017;46:1882–90.
105. Wenbo L, Congxia B, Hui L. Genetic and environmental-genetic interaction rules for the myopia based on a family exposed to risk from a myopic environment. Gene. 2017;626:305–8.
106. Ahn H, Lyu IS, Rim TH. The influence of parental myopia on children’s myopia in different generations of parent-offspring pairs in South Korea. Semin Ophthalmol. 2018;33(3):419–28.
107. Li J, Zhang Q. Insight into the molecular genetics of myopia. Mol Vis. 2017;23:1048–80.
108. Chen Y, Zhang J, Morgan IG, He M. Identifying children at risk of high myopia using population centile curves of refraction. PLoS One. 2016;11(12):e0167642.
109. Guggenheim JA, Ghorbani Mojarrad N, Williams C, et al. Genetic prediction of myopia: prospects and challenges. Ophthalmic Physiol Opt. 2017;37:549–56.
110. Rong SS, Chen LJ, Pang CP. Myopia Genetics-The Asia-Pacific Perspective. Asia Pac J Ophthalmol. 2016;5(4):236–44.
111. Flitcroft DI, Loughman J, Wildsoet CF, Williams C, Guggenheim JA, CREAM Consortium. Novel myopia genes and pathways identified from syndromic forms of myopia. Invest Ophthalmol Vis Sci. 2018;59(1):338–48.
Open Access This chapter is licensed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.

The images or other third party material in this chapter are included in the chapter's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the chapter's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.